Key statistics
On Tuesday, Liquidia Corp (LT4:BER) closed at 10.08, 85.64% above the 52 week low of 5.43 set on Oct 20, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.14 |
---|---|
High | 10.29 |
Low | 10.08 |
Bid | 9.93 |
Offer | 10.14 |
Previous close | 10.08 |
Average volume | 294.00 |
---|---|
Shares outstanding | 84.00m |
Free float | 67.62m |
P/E (TTM) | -- |
Market cap | 936.59m USD |
EPS (TTM) | -1.57 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 20:52 BST.
More ▼
Announcements
- United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent
- Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)
- Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting
- Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million
- Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement
- Liquidia to Present at Upcoming Investor Conferences
- Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD
- U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
- Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions
- Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update
More ▼